Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results

  • Authors:
    • Anna Monica Bianco
    • Flavio Faletra
    • Diego Vozzi
    • Martina Girardelli
    • Alessandra Knowles
    • Alberto Tommasini
    • Giorgio Zauli
    • Annalisa Marcuzzi
  • View Affiliations

  • Published online on: August 11, 2015     https://doi.org/10.3892/mmr.2015.4215
  • Pages: 6128-6132
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Next-generation sequencing (NGS) has generated a large amount of sequence data with the requirement of frequent critical revisions of reported mutations. This innovative tool has proved to be effective in detecting pathogenic mutations; however, it requires a certain degree of experience to identify incidental findings. In the present study, whole exome sequencing analysis was performed for the molecular diagnosis and correct genotype/phenotype correlation between parents and a patient presenting with an atypical phenotype. In addition, mevalonic acid quantification and frequency analysis of detected variants in public databases and X‑chromosome inactivation (XCI) studies on the patient's mother were performed. V377I as well as the S135L mutations were identified on the mevalonate kinase deficiency gene and the levels of mevalonic acid in the patient were 5,496 µg/ml. A D59G variation, reported in ESP6500 in two healthy individuals, was found on the Martin Probst syndrome gene (RAB40AL). Based on XCI studies on the patient's mother, it is likely that RAB40AL escapes XCI, while still remaining balanced. In conclusion, the results of the present study indicated that the Martin Probst syndrome is an X‑linked condition, which is probably not caused by RAB40AL mutations. Although NGS is a powerful tool to identify pathogenic mutations, the analysis of genetic data requires expert critical revision of all detected variants.

Introduction

Next-generation sequencing (NGS) has introduced a novel era, in which it has become possible to rapidly and cost-efficiently obtain large amounts of sequence data for patients. NGS analysis is therefore currently regarded as a first-choice diagnostic tool, particularly in cases in which phenotypical and clinical features are unclear or atypical, leaving Sanger sequencing for the confirmation of detected variants (1). The correct placement of a preliminary clinical diagnosis and subsequent selection of candidate genes for molecular analysis are challenging when patients present with signs and symptoms that do not match any known clinical condition. In these cases, the use of Sanger sequencing to produce a molecular diagnosis is unreasonable due to the high cost and effort required.

In these cases, whole exome sequencing (WES) can be an appropriate tool to detect pathogenic mutations; however, this requires an effective strategy for filtering results and in-depth analysis to meaningfully interpret incidental findings (2,3). Furthermore, in silico and functional studies may be necessary to attribute the correct value to unexpected results.

The present study reports on a patient who was selected, given the clinical phenotype complexity, for proband-parents (trios) analysis using WES with the aim of detecting all the possible genetic variants that may have generated the patient's phenotype.

The present study confirmed that it is essential to filter and confirm each step of the NGS based on the decision of a team that has the necessary expertise to assess the impact of the detected variants.

Materials and methods

Ethical approval

The technical and scientific review board of the Institute for Maternal and Child Health, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 'Burlo Garofolo' (Trieste, Italy) (no. 185/08, 19/08/2008) approved the present study. For enrolment of the child and the parents in the present study, informed consent was obtained from the parents.

Patient

A six-year-old boy with non-consanguineous parents was admitted to the Paediatric Department of the IRCCS 'Burlo Garofolo' (Trieste, Italy) due to neurogenic diabetes insipidus, mild hepatomegaly and recurrent episodes of fever with skin rash and cervical adenitis.

DNA extraction

Genomic DNA (gDNA) was extracted from 1–2 ml EDTA-anticoagulated blood obtained from the proband and his parents using an EZ1 DNA Blood kit (Qiagen, Hilden, Germany) according to manufacturer's instructions.

WES analysis

A total of 3 μg gDNA was used for library preparation using TruSeq™ Exome Enrichment 62 Mb kit (Illumina Inc., San Diego, CA, USA). A paired-end sequencing of each library was performed on an Illumina HiSeq1000 (Illumina Inc.). Raw sequencing data were collected as unmapped 100-bp reads in fastQ format. CLC Genomics Workbench version 6.5 software (CLC Bio; Qiagen) was employed to check the quality of the reads, to map reads back to the human reference genome, version hg19, to calculate the overall coverage, to perform local realignment and base quality recalibration and, finally, to call single nucleotide variants (SNVs) and small insertion/deletions (INDELs). All of these data were collected into a standardized variant call format, version 4.1 (4). SNVs/INDELs were annotated using ANNOVAR software (http://www.openbioinformatics.org/annovar/; version 2013Aug23) referring to several public databases, including National Center of Biotechnology Information dbSNP build138 (http://www.ncbi.nlm.nih.gov/SNP/), the 1000 Genomes Project (http://www.1000genomes.org/) and the National Heart, Lung, and Blood Institute Exome Sequencing Project Exome Variant Server (http://evs.gs.washington.edu/EVS/) (5).

Bioinformatic and statistical analyses

SN Vs/INDELs were first analyzed with the aim of evaluating all known mutations already associated with the clinical manifestations of the patient. Subsequently, SNVs/INDELs were filtered with the purpose of selecting variants which are poorly represented within the general population and potentially 'pathogenic'; to this end, variants were selected according to the following inclusion criteria: A) Minor allelic frequency <0.03 in residents with ancestry from northern and western Europe, referring to the 1000 Genomes Project (http://www.1000genomes.rg/) and NHLBI Exome Sequencing Project (ESP) Exome Variant Server (http://evs.gs.washington.du/EVS/); B) homozygous variants carried by the proband; and C) variants predicted as 'pathogenic' based on Polyphen-2 (6), Mutation Taster and LRT scores, as recorded in dbNSFP v2.0 (7,8).

Polymerase chain reaction (PCR) and Sanger analyses

PCR amplification was performed for the specific genecoding sequences of the MVK and RAB40AL genes. 50 ng DNA was amplified using KAPA 2G Fast Hot Start Readymix (initial concentration, 2X; final concentration, 1X; respective primer initial concentration, 10 μM; final concentration, 0.2 μM; final volume, 25 μl) (Resnova, Roma, Italy) and a 2720 Thermal Cycler (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). Amplification products were purified with ExoSAP-IT enzyme (Affymetrix, Inc., Santa Clara, CA, USA) at 37°C for 20 sec, subsequently inactivated at 85°C for 10 sec, and directly sequenced by the Sanger method using ABI Prism 3.1 Big Dye terminator chemistry (Invitrogen Life Technologies, Carlsbad, CA, USA) and BigDye XTerminator Purification kit (Applied Biosystems). Runs were performed on the ABI Prism 3130XL automated DNA sequencer (Applied Biosystems). Sequences were analyzed with Seqman II Software (DNASTAR I Lasergene 7.0; DNASTAR, Madison, WI, USA). PCR amplification and Sanger sequencing primers to confirm the MVK (NM_000431) mutations (c.1129G>A; p.V377I) and (c.404C>T; p.S135L) were: MVK5 forward, 5′-GTTGAGAAAACTGGACCAGATGC-3′ and MVK5 reverse, 5′-CTCAGCTTCCTCATGTTAAAATG-3′; and MVK11 forward, 5′-GGCTTTTGCCTTGAATATGATGA-3′ and MVK11 reverse, 5′-GGGCCTCTCCAGCAGTGTC-3′. PCR amplification and Sanger sequencing primers to confirm the RAB40AL (NM_001031834) known dinucleotide missense changes c.A176G and c.C177A, leading top.D59G were: RAB40AL forward, 5′-CCTCTGCGCACAACCTTGC-3′ and RAB40AL reverse, 5′-CTGGAGCGATTCCAGCTTG-3′. Primers were obtained from Integrated DNA Technologies (Coralville, IA, USA). PCR amplification cycle: Initial denaturation (95°C for 1 sec), 30 cycles of denaturation (95°C for 10 sec), annealing (60°C for 10 sec) and elongation (72°C for 5 sec), followed by a final elongation (72°C for 30 sec). Sequence reaction cycle: Initial denaturation (96°C for 3 sec), 26 cycles of denaturation (96°C for 30 sec), annealing (53°C for 15 sec) and elongation (60°C for 4 sec).

RAB40AL inactivation analysis

300 ng genomic DNA of the patient was digested with 40 U HpaII methylation-sensitive restriction enzyme and 20 U RsaI methylation-insensitive restriction enzyme (New England Biolabs, Ipswich, MA, USA) in a total volume of 20 μl for 24 h at 37°C. After digestion, the mixtures were incubated at 95°C for 10 min. 50 ng digested and undigested DNA were amplified with RAB40AL forward and reverse primers as previously described to verify the inactivation of the gene.

X-chromosome inactivation (XCI) analysis via androgen receptor

300 ng genomic DNA of the patient's mother was digested as described above and incubated at 95°C for 10 min. 50 ng of digested and undigested DNA was amplified with primers 5′-GCTGTGAAGGTTGCTGTTCCTCAT-3′ and 5′–56-FAM/TCCAGAATCTGTTCCAGAGCGTGC-3′ according to the protocol of a previous study (9) for amplification of a region of the human androgen receptor (HAR) gene, localized on Xq12 and characterized by a polymorphic number of CAG repeats. Since this fragment has two HpaII restriction enzyme sites, only methylated DNA was amplified.

XCI analysis via the polymorphic marker DXS1214

300 ng genomic DNA of the patient's mother was digested as described above and incubated at 95°C for 10 min. 50 ng digested and undigested DNA was a mplified with specific DXS1214-labeled primers.

The labeled PCR products were denatured and run on the automated sequencer (ABI 3730XL Platform; Applied Biosystems) using the POP7 polymer and the ROX size standard as size markers (Invitrogen Life Technologies, Inc.). GeneMapper software (v. 4.0; Applied Biosystems) was used for fragment analysis.

Biochemical analysis

Urinary mevalonic acid was determined by means of gas chromatography/mass spectrometry. Spectra were obtained using a Hewlett Packard gas chromatograph 6890 series equipped with a Hewlett Packard 5973 quadrupole operating in electron-impact mode at 70 eV (Hewlett Packard, Palo Alto, CA, USA) (10).

Results and Discussion

WES revealed two missense mutations of the MVK gene (heterozygous): NM_000431, c.1129G>A; p.V377I (rs28934897); and NM-000431, c.404C>T; p.S135L (rs104895297). In addition, the known dinucleotide missense mutations of the RAB40AL (NM_001031834) gene were detected: c. A176G (rs145606134) and c. C177A (rs138133927), leading to p.D59G. Sanger sequencing analysis confirmed all mutations. No mutations were detected in genes associated with diabetes insipidus.

The MVK gene encodes mevalonate kinase, the third enzyme on the pathway leading to the synthesis of cholesterol from acetyl-CoA (11). Mutations of the MVK gene cause a recessive inherited disease called mevalonate kinase deficiency (MKD), which manifests as a clinical and biochemical continuum with mevalonic aciduria at the most severe end [MA; online mendelian of inheritance in man (OMIM) #610377] and hyper immunoglobulin D and periodic fever syndrome at the mildest end (HIDS; OMIM #260920) (12).

The D59G variant of RAB40AL has already been reported as causative of the Martin-Probst syndrome (MPS; OMIM #300519), a recessive X-linked disease characterized by congenital sensorineural hearing loss, mental retardation, short stature, congenital umbilical hernia, facial dysmorphism, abnormal teeth, widely spaced nipples and abnormal dermatoglyphics (13,14). In the present study, a multidisciplinary team discussed the relevance of the genetic results in order to compare the patient's clinical features with those pertaining to MKD and MPS, based on clinical, genetic and functional evaluations.

The diagnosis of MKD was supported not only by the fact that the two mutations detected have a well known role in the disease, but also by a biochemical analysis that demonstrated the accumulation of mevalonic acid [5,496 μg/ml; the normal range of mevalonic acid levels is 34–323 μg/ml (internal laboratory reference)] in urine during febrile crisis, as a proof of MK enzyme deficiency (10).

In the case of the present study, the diagnosis of MKD adequately explained the proband's condition, apart from the presence of neurogenic diabetes insipidus (Table I).

Table I

Main symptoms for MP syndrome and MK deficiency compared with the symptoms of patient of the present study.

Table I

Main symptoms for MP syndrome and MK deficiency compared with the symptoms of patient of the present study.

FeatureMP syndromeMK deficiencyPatient
GrowthShort statureFrom failure to thrivea to normal; hyper immunoglobulin D; periodic fever syndromeNormal
HeadMicrocephalyMicrocephalyaNormal
EarsHearing lossNormalNormal
EyeNormalCentral cataractsaNormal
DysmorphismsLow-set ears
Telecanthus
Hypertelorism
Epicanthal folds
Broad nasal root
Broad mouth
Full lower lip
Abnormal teeth
Triangular facea, Hypoplastic alae nasiaNormal
GenitourinaryBifid scrotum
Small phallus
Cryptorchidism
Hypoplastic kidneys
Renal insufficiency
NormalNormal
SkinTelangiectasiasSkin rashesSkin rashes
Central nervous systemMental retardation, mild to severePsychomotor retardationa, Cerebella ataxiaaNeurogenic diabetes insipidus
Osteoarticular systemNormal Arthralgia/arthritisNormal
Endocrine featuresHypothyroidismNormalNormal
HematologyPancytopeniaAnemiaMild anemia
Lymphoid organsLeukopeniaLymphadenopathy, hepato-splenomegalyLymphadenopathy, hepato-splenomegaly
Molecular BasisRAB40ALMVKMVK V377I/S135L
RAB40AL D59G

a Phenotypic features of mevalonic aciduria. MV, mevalonate kinase; MP, Martin Probst.

In fact, most of the clinical features of the patient are characteristics of MKD, although a large number of MKD-associated symptoms were not present in the patient. In particular, diabetes insipidus, which was one of the main complaints of the patient, is not characteristic of MKD. By contrast, no sign or symptom of MPS was present in the patient. Since MPS is described as an X-recessive disease with complete penetrance, it was unexpected that the patient had not developed any of the severe impairments, which are typical of the disease. It was thus hypothesized that either the defect in MK has a protective effect against the development of MPS or that the variant detected in RAB40AL is not the actual cause of MPS. Of note, the variant identified in RAB40AL was predicted to affect protein farnesylation; however, MKD is also associated with an abnormal pattern of protein prenylation due to a shortage of mevalonate-derived isoprenoids (15,16). However, considering that the two defects can reduce protein farnesylation, the combined effect of the two defects would have been expected to be even more severe. On the contrary, the National Heart, Lung and Blood Institute-exome sequencing project (ESP)6500 database (http://evs.gs.washington.edu/EVS/) lists two healthy males carrying the D59G variant of RAB40AL, suggesting that it represents an irrelevant albeit rare polymorphism. In addition, recent studies described the same RAB40AL variant in a patient with a distinctly different phenotype from that reported in MPS patients (17,18).

To ascertain the possibility that RAB40AL is not the causative gene of MPS, the present study exploited the opportunity of studying the mother of the patient, who is a heterozygous carrier of the same gene variant. Bedoyan et al (13) demonstrated that, while males affected by MPS develop progressive loss of white blood cells, female carriers have a normal leukocyte count and display a skewed XCI in peripheral blood cells. The present study then attempted to analyze the inactivation profile of RAB40AL by amplifying the gene after digestion with a methylation-sensitive enzyme (19,20). However, it was not possible to amplify RAB40AL after HpaII digestion, suggesting that this gene escapes inactivation (Fig. 1A). In order to verify the hypothesis of a skewed XCI, the present study then used polymorphic X-chromosome markers known to undergo methylation and inactivation. As the most widely used androgen receptor humara locus was uninformative in the patient's family, the polymorphic marker DXS1214 was then analyzed. After digestion with HpaII, which is selective for active unmethylated DNA, the two DXS1214 polymorphic alleles remained present to similar extents, confirming a balanced XCI (Fig. 1B). These results suggested that the pattern of skewed XCI in the family examined by Bedoyan et al (13) is not due to the D59G variant in RAB40AL, but to another unidentified X-chromosome gene mutation. In conclusion, these results suggested that mutations of RAB40AL are not the cause of MPS.

The case of the present study confirmed the potential of the NGS technique to identify pathogenic and causative mutations, but also highlighted the crucial role of an expert team performing the critical revision of all detected WES variants.

Acknowledgments

The authors would like to thank the patient and his family for participating in this study. This work was supported by an Intramural grant of the Institute for Maternal and Child Health (IRCCS 'Burlo Garofolo', Trieste, Italy). The present study was also supported by the 'Associazione Azzurra Malattie Rare' and 'Beneficentia Stiftung in Vaduz, Liechtenstein'.

References

1 

van Dijk EL, Auger H, Jaszczyszyn Y and Thermes C: Ten years of next-generation sequencing technology. Trends Genet. 30:418–426. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Pelak K, Shianna KV, Ge D, Maia JM, Zhu M, Smith JP, Cirulli ET, Fellay J, Dickson SP, Gumbs CE, et al: The characterization of twenty sequenced human genomes. PLoS Genet. 6:e10011112010. View Article : Google Scholar : PubMed/NCBI

3 

Robinson PN, Krawitz P and Mundlos S: Strategies for exome and genome sequence data analysis in disease gene discovery projects. Clin Genet. 80:127–132. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker RE, Lunter G, Marth GT, Sherry ST, et al 1000 Genomes Project Analysis Group: The variant call format and VCF tools. Bioinformatics. 27:2156–2158. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Wang K, Li M and Hakonarson H: ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI

6 

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods. 7:248–249. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Schwarz JM, Rödelsperger C, Schuelke M and Seelow D: MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 7:575–576. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Liu X, Jian X and Boerwinkle E: dbNSFP v2.0: A database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat. 34:E2393–E2402. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Tilley WD, Marcelli M, Wilson JD and McPhaul MJ: Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA. 86:327–331. 1989. View Article : Google Scholar : PubMed/NCBI

10 

Shoemaker JD and Elliott WH: Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. J Chromatogr A. 562:125–138. 1991. View Article : Google Scholar

11 

Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI

12 

Haas D and Hoffmann GF: Mevalonate kinase deficiencies: From mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 1:132006. View Article : Google Scholar : PubMed/NCBI

13 

Bedoyan JK, Schaibley VM, Peng W, Bai Y, Mondal K, Shetty AC, Durham M, Micucci JA, Dhiraaj A, Skidmore JM, et al: Disruption of RAB40AL function leads to Martin-Probst syndrome, a rare X-linked multisystem neurodevelopmental human disorder. J Med Genet. 49:332–340. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Lee J, Wong S and Boles RG: Mutation in the X-linked RAB40AL gene (Martin-Probst syndrome) with mental retardation, sensorineural hearing loss, and anomalies of the craniofacies and genitourinary tract: A second case report. Eur J Pediatr. 173:967–969. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Mandey SH, Schneiders MS, Koster J and Waterham HR: Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat. 27:796–802. 2006. View Article : Google Scholar : PubMed/NCBI

16 

Marcuzzi A, Pontillo A, De Leo L, Tommasini A, Decorti G, Not T and Ventura A: Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. Pediatr Res. 64:177–182. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Ołdak M, Ścieżyńska A, Młynarski W, Borowiec M, Ruszkowska E, Szulborski K, Pollak A, Kosińska J, Mueller-Malesińska M, Stawiński P, et al: Evidence against RAB40AL being the locus for Martin-Probst X-linked deafness-intellectual disability syndrome. Hum Mutat. 35:1171–1174. 2014. View Article : Google Scholar

18 

Kalscheuer V, Iqbal Z, Hu H, et al: RAB40AL loss-of-function mutation does not cause X-linked intellectual disability. J Med Genet: Reply to reference. 1:2013.

19 

Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM and Belmont JW: Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 51:1229–1239. 1992.PubMed/NCBI

20 

Wolf SF, Jolly DJ, Lunnen KD, Friedmann T and Migeon BR: Methylation of the hypoxanthine phosphoribosyltrans-ferase locus on the human X chromosome: Implications for X-chromosome inactivation. Proc Natl Acad Sci USA. 81:2806–2810. 1984. View Article : Google Scholar

Related Articles

Journal Cover

October-2015
Volume 12 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bianco AM, Faletra F, Vozzi D, Girardelli M, Knowles A, Tommasini A, Zauli G and Marcuzzi A: Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results. Mol Med Rep 12: 6128-6132, 2015
APA
Bianco, A.M., Faletra, F., Vozzi, D., Girardelli, M., Knowles, A., Tommasini, A. ... Marcuzzi, A. (2015). Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results. Molecular Medicine Reports, 12, 6128-6132. https://doi.org/10.3892/mmr.2015.4215
MLA
Bianco, A. M., Faletra, F., Vozzi, D., Girardelli, M., Knowles, A., Tommasini, A., Zauli, G., Marcuzzi, A."Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results". Molecular Medicine Reports 12.4 (2015): 6128-6132.
Chicago
Bianco, A. M., Faletra, F., Vozzi, D., Girardelli, M., Knowles, A., Tommasini, A., Zauli, G., Marcuzzi, A."Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results". Molecular Medicine Reports 12, no. 4 (2015): 6128-6132. https://doi.org/10.3892/mmr.2015.4215